U.S. RESEARCH ROUNDUP-Abbvie, Lionsgate Studios, UnitedHealth Group

Reuters06-05

June 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies, including Abbvie, Lionsgate Studios and UnitedHealth Group on Wednesday.

HIGHLIGHTS

* Abbvie Inc : HSBC raises to buy from hold

* Crowdstrike Holdings Inc : BTIG cuts target price to $402 from $432

* Lionsgate Studios : Seaport Research Partners initiates coverage with

neutral rating

* Sunoco LP : JP Morgan assumes coverage with overweight vs neutral rating

* UnitedHealth Group Inc : HSBC raises to buy from hold

Following is a summary of research actions on U.S. companies reported by Reuters on Wednesday. Stock entries are in alphabetical order.

* Abbvie Inc : HSBC raises target price to $185 from $161

* Abbvie Inc : HSBC raises to buy from hold

* Adobe Inc : RBC cuts target price to $600 from $630

* Alnylam Pharmaceuticals Inc : JP Morgan cuts target price to $160 from $166

* Annexon Inc : JP Morgan raises target price to $12 from $11

* $Aramark(ARMK-W)$ : Jefferies raises target price to $37 from $35

* Aris Water Solutions Inc : Citigroup raises target price to $18 from $14

* Boot Barn Holdings Inc : BTIG raises target price to $150 from $125

* Boot Barn Holdings Inc : TD Cowen raises target price to $145 from $120

* Bridgebio pharma Inc : JP Morgan raises target price to $46 from $44

* Core & Main Inc : Truist Securities cuts target price to $50 from $56

* Crowdstrike Holdings Inc : BTIG cuts target price to $402 from $432

* Crowdstrike Holdings Inc : Canaccord Genuity raises PT to $405 from $400

* Crowdstrike Holdings Inc : D.A. Davidson cuts target price to $380 from $425

* Donaldson Company Inc : Jefferies raises target price to $81 from $77

* Factset Research Systems Inc : Jefferies cuts target price to $378 from $455

* Ferguson : Barclays cuts target price to $232 from $236

* Ferguson : Jefferies cuts target price to $238 from $244

* Ferguson : RBC cuts target price to $211 from $217

* Guidewire Software Inc : BTIG raises target price to $140 from $135

* Guidewire Software Inc : JP Morgan raises target price to $145 from $133

* Guidewire Software Inc : Raymond James raises target price to $130 from $125

* Hewlett Packard Enterprise Co : Evercore ISI raises target price to $22 from $18

* Honeywell International Inc : Daiwa Capital Markets raises PT to $217 from $200

* Ideaya Biosciences Inc : JP Morgan raises target price to $65 from $55

* Illinois Tool Works Inc : JP Morgan cuts target price to $275 from $280

* Ionis Pharmaceuticals Inc : JP Morgan cuts target price to $50 from $55

* Labcorp : HSBC cuts target price to $210 from $225

* Lionsgate Studios : Seaport Research Partners initiates coverage with neutral rating

* Magnite Inc : RBC raises target price to $19 from $17

* Mainz Biomed NV : Jonestrading cuts target price to $4 from $8

* Merck & Co Inc : HSBC raises target price to $130 from $118

* Phreesia Inc : Jefferies cuts target price to $28 from $32

* PVH Corp : Evercore ISI raises target price to $145 from $140

* Sensei Biotherapeutics Inc : Citigroup resumes coverage with buy rating; PT $4

* Siteone Landscape Supply Inc : Barclays cuts target price to $129 from $133

* Snowflake Inc : RBC cuts target price to $183 from $226

* Steven Madden Ltd : Jefferies raises target price to $42 from $39

* Sunoco LP : JP Morgan assumes coverage with overweight vs neutral rating

* Sunoco LP : JP Morgan assumes coverage with target price $61 vs $60

* UnitedHealth Group Inc : HSBC raises target price to $580 from $460

* UnitedHealth Group Inc : HSBC raises to buy from hold

* Verint Systems Inc : Jefferies raises target price to $32 from $30

* Viking Therapeutics Inc : Leerink Partners raises PT to $118 from $115

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment